Montreal-based Fonds de solidarité FTQ has invested $5 million in Dartmouth-based immunotherapy company IMV as part of the company’s recent public offering, which raised almost $30 million.
It is the second investment in IMV by the Fonds, which has almost $15 billion in assets and channels Quebecers’ savings into investments. It previously invested $5.75 million in the company in February 2018.
The funding will be used to develop new cancer immunotherapies using DPX-Survivac, IMV’s proprietary drug release platform, said the statement. With offices and laboratories in Halifax and Québec